Results 11 to 20 of about 205 (161)

Human minor histocompatibility antigens

Transplant Immunology, 1993
For over five decades minor histocompatibility (mH) antigens have contmued to fascmate immimologists, mainly because of their minor but distinct role in transplantation but no less because of their as yet unknown nature In the 1970s lt became evident that mH antigens were recognized in a MHC restncted fashion, an important feature which was poorly ...
M, de Bueger, E, Goulmy
  +8 more sources

Prognostic significance of tumor microenvironment assessed by machine learning algorithm in surgically resected non‐small cell lung cancer

Cancer Reports, EarlyView., 2023
Abstract Background A methodology to assess the immune microenvironment (IME) of non‐small cell lung cancer (NSCLC) has not been established, and the prognostic impact of IME factors is not yet clear. Aims This study aimed to assess the IME factors and evaluate their prognostic values. Methods and Results We assessed CD8+ tumor‐infiltrating lymphocyte (
Yukihiro Terada, Mitsuhiro Isaka, Akira Ono, Takuya Kawata, Masakuni Serizawa, Keita Mori, Koji Muramatsu, Kiyoshi Tone, Hirotsugu Kenmotsu, Keiichi Ohshima, Kenichi Urakami, Takeshi Nagashima, Masatoshi Kusuhara, Yasuto Akiyama, Takashi Sugino, Toshiaki Takahashi, Yasuhisa Ohde   +16 more
wiley   +1 more source

Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase

Frontiers in Immunology, 2020
Minor histocompatibility antigens are the main targets of donor-derived T-cells after allogeneic stem cell transplantation. Identification of these antigens and understanding their biology are a key requisite for more insight into how graft vs.
Anita N. Kremer, Judith Bausenwein, Ellie Lurvink, Andreas E. Kremer, Caroline E. Rutten, Cornelis A. M. van Bergen, Sascha Kretschmann, Edith van der Meijden, Maria W. Honders, Daniela Mazzeo, Colin Watts, Andreas Mackensen, J. H. Frederik Falkenburg, Marieke Griffioen   +13 more
doaj   +1 more source

Successful generation of primary virus-specific and anti-tumor T-cell responses from the naïve donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells

Haematologica, 2011
Background One of the major challenges in allogeneic stem cell transplantation is to find a balance between the harmful induction of graft-versus-host disease and the beneficial graft-versus-leukemia and pathogen-specific immune responses.
Inge Jedema, Marian van de Meent, Jeanette Pots, Michel G.D. Kester, Martha T. van der Beek, J.H. Frederik Falkenburg   +5 more
doaj   +1 more source

Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens

Frontiers in Immunology, 2020
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor
Kyra J. Fuchs, M. Willy Honders, Edith D. van der Meijden, Edith D. van der Meijden, Alwin E. Adriaans, Dyantha I. van der Lee, Margot J. Pont, Margot J. Pont, Ramin Monajemi, Szymon M. Kielbasa, Peter A. C. ’t Hoen, Peter A. C. ’t Hoen, Cornelis A. M. van Bergen, J. H. Frederik Falkenburg, Marieke Griffioen   +14 more
doaj   +1 more source

Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations.

PLoS Genetics, 2007
Minor histocompatibility (H) antigens are allogeneic target molecules having significant roles in alloimmune responses after human leukocyte antigen-matched solid organ and stem cell transplantation (SCT).
Eric Spierings, Matthijs Hendriks, Léna Absi, Angelica Canossi, Sonal Chhaya, John Crowley, Harry Dolstra, Jean-François Eliaou, Tom Ellis, Jürgen Enczmann, Maria E Fasano, Thibaut Gervais, Clara Gorodezky, Brigitte Kircher, David Laurin, Mary S Leffell, Pascale Loiseau, Mari Malkki, Miroslaw Markiewicz, Miryam Martinetti, Etsuko Maruya, Narinder Mehra, Fatma Oguz, Machteld Oudshoorn, Noemi Pereira, Rajni Rani, Ruhena Sergeant, Jackie Thomson, Thuong Hien Tran, Hannu Turpeinen, Kuo-Liang Yang, Renata Zunec, Mary Carrington, Peter de Knijff, Els Goulmy   +34 more
doaj   +1 more source

The Genomic Landscape of Antigenic Targets for T Cell-Based Leukemia Immunotherapy

Frontiers in Immunology, 2019
Intensive fundamental and clinical research in cancer immunotherapy has led to the emergence and evolution of two parallel universes with surprisingly little interactions: the realm of hematologic malignancies and that of solid tumors.
Marie-Pierre Hardy, Krystel Vincent, Claude Perreault   +2 more
doaj   +1 more source

A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform

Frontiers in Immunology, 2021
The bone marrow transplantation (BMT) between haplo-identical combinations (haploBMT) could cause unacceptable bone marrow graft rejection and graft-versus-host disease (GVHD).
Hisanori Mayumi
doaj   +1 more source

T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect

Nature Communications, 2020
In hematopoietic stem cell transplants, T cells mediate graft-versus-leukemia (GVL), but GVL can fail leading to leukemia relapse. Here the authors use a mouse model in which T cells target the minor histocompatibility antigen H60 to show how this can ...
Meng Zhou, Faruk Sacirbegovic, Kai Zhao, Sarah Rosenberger, Warren D. Shlomchik   +4 more
doaj   +1 more source

Enhancement of Antigen Presentation by Deletion of Viral Immune Evasion Genes Prevents Lethal Cytomegalovirus Disease in Minor Histocompatibility Antigen-Mismatched Hematopoietic Cell Transplantation

Frontiers in Cellular and Infection Microbiology, 2020
Hematoablative treatment followed by hematopoietic cell transplantation (HCT) for reconstituting the co-ablated immune system is a therapeutic option to cure aggressive forms of hematopoietic malignancies.
Emin Gezinir, Jürgen Podlech, Kerstin M. Gergely, Sara Becker, Matthias J. Reddehase, Niels A. W. Lemmermann   +5 more
doaj   +1 more source